PMID- 35134311
OWN - NLM
STAT- MEDLINE
DCOM- 20220524
LR  - 20230916
IS  - 1615-7109 (Electronic)
IS  - 1203-4754 (Print)
IS  - 1203-4754 (Linking)
VI  - 26
IP  - 3
DP  - 2022 May-Jun
TI  - Effect of Nicotinamide in Skin Cancer and Actinic Keratoses Chemoprophylaxis, and 
      Adverse Effects Related to Nicotinamide: A Systematic Review and Meta-Analysis.
PG  - 297-308
LID - 10.1177/12034754221078201 [doi]
AB  - BACKGROUND: Oral nicotinamide is recommended in individuals with a field of 
      cancerization or with >/=1 previous cutaneous squamous cell carcinoma (cSCC). 
      OBJECTIVE: To evaluate the effect of nicotinamide in prevention of skin cancers. 
      METHODS: We conducted a systematic review and meta-analysis of randomized 
      controlled trials to evaluate the effect of nicotinamide. We used Medline, 
      EMBASE, CENTRAL, and Web of Science databases from their inception to October 
      2020 to search the following concepts: "nicotinamide"; "randomized controlled 
      trial" (validated filters). Two independent reviewers screened titles and 
      abstracts for intervention and study design before searching full texts for 
      eligibility criteria. To be eligible, >/=1 outcome had to be covered. We used a 
      standardized collection grid to complete data extraction in duplicate. The 
      primary outcome was skin cancers (all types). Secondary outcomes were basal cell 
      carcinomas (BCCs); cSCCs; actinic keratoses; melanomas; digestive, cutaneous, and 
      biochemical adverse effects (AEs). Subgroup analyses were planned a priori. 
      RESULTS: We screened 4730 citations and found 29 trials (3039 patients) meeting 
      inclusion criteria. Nicotinamide was associated with a significant reduction in 
      skin cancers compared to control (rate ratio 0.50 (95% CI, 0.29-0.85; I (2) = 
      64%; 552 patients; 5 trials); moderate strength of the evidence). Heterogeneity 
      was explained by risk of bias. Nicotinamide was associated with a significant 
      reduction in BCCs and cSCCs, and increased risk of digestive AEs. CONCLUSION: 
      Oral nicotinamide should be considered in healthy patients or organ transplant 
      recipients with history of skin cancer (GRADE: weak recommendation; 
      moderate-quality evidence), in particular of BCC and cSCC.
FAU - Mainville, Laurence
AU  - Mainville L
AUID- ORCID: 0000-0001-8026-5102
AD  - 4440 Faculty of Medicine, Laval University, Quebec, Canada.
FAU - Smilga, Anne-Sophie
AU  - Smilga AS
AUID- ORCID: 0000-0001-7625-6019
AD  - 4440 Faculty of Medicine, Laval University, Quebec, Canada.
FAU - Fortin, Paul R
AU  - Fortin PR
AD  - 177453 Infectious and Immune Diseases, Centre de recherche du CHU de Quebec - 
      Universite Laval, Quebec, Canada.
AD  - Division of Rheumatology, Department of Medicine, CHU de Quebec - Universite 
      Laval, Quebec, Canada.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20220208
PL  - United States
TA  - J Cutan Med Surg
JT  - Journal of cutaneous medicine and surgery
JID - 9614685
RN  - 25X51I8RD4 (Niacinamide)
SB  - IM
MH  - *Carcinoma, Basal Cell/pathology/prevention & control
MH  - *Carcinoma, Squamous Cell/pathology/prevention & control
MH  - Chemoprevention/adverse effects
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - Humans
MH  - *Keratosis, Actinic/prevention & control
MH  - Niacinamide/adverse effects
MH  - *Skin Neoplasms/pathology
PMC - PMC9125143
OTO - NOTNLM
OT  - actinic keratosis
OT  - adverse effect
OT  - basal cell carcinoma
OT  - chemoprevention
OT  - chemoprophylaxis
OT  - cutaneous squamous cell carcinoma
OT  - melanoma
OT  - niacinamide
OT  - nicotinamide
OT  - oncology
OT  - skin cancer
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2022/02/09 06:00
MHDA- 2022/05/25 06:00
PMCR- 2022/05/23
CRDT- 2022/02/08 20:15
PHST- 2022/02/09 06:00 [pubmed]
PHST- 2022/05/25 06:00 [medline]
PHST- 2022/02/08 20:15 [entrez]
PHST- 2022/05/23 00:00 [pmc-release]
AID - 10.1177_12034754221078201 [pii]
AID - 10.1177/12034754221078201 [doi]
PST - ppublish
SO  - J Cutan Med Surg. 2022 May-Jun;26(3):297-308. doi: 10.1177/12034754221078201. 
      Epub 2022 Feb 8.